LENZ LENZ Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$5.16

Period return

-16.11 (-75.74%)

Volume

744.8K

2026-07-21O $4.89 H $5.16 L $4.89 C $5.16MA5 $5.03MA20 $5.51MA60 $7.03MA120 $9.41

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 29.Highin 8 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.00%
2026. 05. 14.LowBUY2 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 05. 12.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 12.MediumHOLD2 months ago
Piper Sandler: Neutral
US analyst rating / recommendation change.
2026. 04. 21.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 27.LowBUY4 months ago
Citigroup: Buy
US analyst rating / recommendation change.
2026. 03. 25.LowBUY4 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2025. 10. 21.LowBUY9 months ago
Raymond James: Outperform
US analyst rating / recommendation change.
2025. 10. 10.LowBUY9 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $32

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Solana Beach, CA, United States
Fiscal year end: —
Employees: 152
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 29.	After market close (AMC)	$-1.07	—	—	$2.49M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.53	—	—	$0	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	293,446	$4.7M	0.01%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	500,997	$4.58M	0.00%	—	New position

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 05. 12.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 12.	Piper Sandler	—	Downgrade	Overweight → Neutral	—	Piper Sandler: Overweight → Neutral
2026. 04. 21.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 27.	Citigroup	—	Maintain	Buy → Buy	—	Citigroup: Buy
2026. 03. 25.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy